HK1244201A1 - 芋螺毒素(conotoxin)肽的修饰和用途 - Google Patents
芋螺毒素(conotoxin)肽的修饰和用途 Download PDFInfo
- Publication number
- HK1244201A1 HK1244201A1 HK18103429.5A HK18103429A HK1244201A1 HK 1244201 A1 HK1244201 A1 HK 1244201A1 HK 18103429 A HK18103429 A HK 18103429A HK 1244201 A1 HK1244201 A1 HK 1244201A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- pain
- conotoxin peptides
- modifications
- rgia
- conotoxin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43509—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from crustaceans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Insects & Arthropods (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462123123P | 2014-11-07 | 2014-11-07 | |
| US201462123123P | 2014-11-07 | ||
| PCT/US2015/059613 WO2016073949A1 (en) | 2014-11-07 | 2015-11-06 | Modifications and uses of conotoxin peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1244201A1 true HK1244201A1 (zh) | 2018-08-03 |
Family
ID=55909927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18103429.5A HK1244201A1 (zh) | 2014-11-07 | 2015-11-06 | 芋螺毒素(conotoxin)肽的修饰和用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11014970B2 (enExample) |
| EP (1) | EP3215172B1 (enExample) |
| JP (3) | JP6798998B2 (enExample) |
| KR (1) | KR102623475B1 (enExample) |
| CN (1) | CN107249616A (enExample) |
| AU (2) | AU2015342767B2 (enExample) |
| CA (1) | CA2966865C (enExample) |
| ES (1) | ES2950901T3 (enExample) |
| HK (1) | HK1244201A1 (enExample) |
| IL (2) | IL284236B2 (enExample) |
| TW (2) | TWI708790B (enExample) |
| WO (1) | WO2016073949A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI708790B (zh) | 2014-11-07 | 2020-11-01 | 美商奇尼塔慢性疼痛有限責任公司 | 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途 |
| RU2731217C2 (ru) * | 2016-11-28 | 2020-08-31 | Общество с ограниченной ответственностью "Синейро" | Аналог альфа-конотоксина RgIA для лечения боли |
| US10947274B1 (en) * | 2018-05-01 | 2021-03-16 | University Of Utah Research Foundation | Synthetic analgesic peptides of RgIA analogs |
| KR102117106B1 (ko) | 2018-09-14 | 2020-06-01 | 대한민국(환경부 국립생물자원관장) | N형 칼슘채널 차단 활성을 갖는 긴호랑거미 유래 알지신-ⅰ 펩타이드 및 이의 용도 |
| US11612661B2 (en) | 2019-01-04 | 2023-03-28 | Kineta Chronic Pain, Llc | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
| AU2019418319B2 (en) * | 2019-01-04 | 2025-08-21 | Pacira Pharmaceuticals, Inc. | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
| JP2023523899A (ja) * | 2020-04-09 | 2023-06-08 | ジーエルオー ファーマ，インク． | ニコチン性アセチルコリン受容体活性を阻害するためのペプチド組成物および方法 |
| KR20230031884A (ko) * | 2020-06-03 | 2023-03-07 | 유타대학연구재단 | 형태적으로 제약된 α-RGIA 유사체 |
| CN114805492B (zh) * | 2022-03-15 | 2025-07-22 | 上海元炘执药科技有限公司 | 一种用于抑制电压门控钠离子通道1.4的芋螺毒素kiiia突变体及其制备方法和应用 |
| CN115286700B (zh) * | 2022-08-22 | 2024-11-19 | 中国海洋大学 | 一种具有血浆稳定性的镇痛多肽 |
| CN118184744A (zh) * | 2024-03-29 | 2024-06-14 | 广西大学 | 一种靶向神经型乙酰胆碱受体的多肽分子及其制备方法和应用 |
| CN119912549A (zh) * | 2024-12-29 | 2025-05-02 | 中国人民解放军军事科学院防化研究院 | 一类脂肪醛修饰的芋螺肽及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595972A (en) | 1993-06-29 | 1997-01-21 | University Of Utah Research Foundation | Conotoxin peptides |
| US6797808B1 (en) | 1999-01-29 | 2004-09-28 | University Of Utah Research Foundation | α-conotoxin peptides |
| HUP0203504A3 (en) | 1999-10-18 | 2005-03-29 | Akzo Nobel Nv | Modified peptides and peptidomimetics for use in immunotherapy |
| EP1578787B1 (en) | 2002-12-02 | 2012-11-14 | Xenome Ltd | Novel chi-conotoxin peptides (-ii) |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| EP1770099A1 (en) * | 2005-09-28 | 2007-04-04 | University of Geneva | Method of producing a modified (poly)peptide |
| US7745573B2 (en) | 2006-02-17 | 2010-06-29 | Polychip Pharmaceuticals Pty Ltd. | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| CA2566832A1 (en) * | 2006-04-13 | 2007-10-13 | The University Of Queensland | Cyclised alpha-conotoxin peptides |
| US9284358B2 (en) * | 2006-07-18 | 2016-03-15 | University Of Utah Research Foundation | Conotoxin peptides |
| WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| EP2310407A4 (en) | 2008-04-08 | 2011-09-14 | Aileron Therapeutics Inc | BIOLOGICALLY ACTIVE PEPTIDOMIMETIC MACROCYCLES |
| DE102009050885A1 (de) * | 2009-10-27 | 2011-04-28 | Behr Gmbh & Co. Kg | Luftausströmer |
| WO2014194284A1 (en) | 2013-05-31 | 2014-12-04 | Mcintosh J Michael | Conotoxin peptides, pharmaceutical compositions and uses thereof |
| TWI708790B (zh) | 2014-11-07 | 2020-11-01 | 美商奇尼塔慢性疼痛有限責任公司 | 芋螺毒素（ｃｏｎｏｔｏｘｉｎ）肽之修飾及用途 |
| US11612661B2 (en) | 2019-01-04 | 2023-03-28 | Kineta Chronic Pain, Llc | Conotoxin peptide analogs and uses for the treatment of pain and inflammatory conditions |
-
2015
- 2015-11-06 TW TW104136722A patent/TWI708790B/zh not_active IP Right Cessation
- 2015-11-06 EP EP15856496.3A patent/EP3215172B1/en active Active
- 2015-11-06 CN CN201580068468.7A patent/CN107249616A/zh active Pending
- 2015-11-06 US US15/525,024 patent/US11014970B2/en active Active
- 2015-11-06 JP JP2017544555A patent/JP6798998B2/ja active Active
- 2015-11-06 CA CA2966865A patent/CA2966865C/en active Active
- 2015-11-06 HK HK18103429.5A patent/HK1244201A1/zh unknown
- 2015-11-06 AU AU2015342767A patent/AU2015342767B2/en active Active
- 2015-11-06 IL IL284236A patent/IL284236B2/en unknown
- 2015-11-06 WO PCT/US2015/059613 patent/WO2016073949A1/en not_active Ceased
- 2015-11-06 TW TW109134130A patent/TWI777260B/zh not_active IP Right Cessation
- 2015-11-06 KR KR1020177015279A patent/KR102623475B1/ko active Active
- 2015-11-06 ES ES15856496T patent/ES2950901T3/es active Active
-
2017
- 2017-05-07 IL IL252152A patent/IL252152B/en unknown
-
2020
- 2020-03-10 JP JP2020040876A patent/JP2020090550A/ja not_active Withdrawn
- 2020-09-29 US US17/037,521 patent/US11618772B2/en active Active
-
2021
- 2021-08-03 AU AU2021212006A patent/AU2021212006B2/en active Active
-
2022
- 2022-01-26 JP JP2022010036A patent/JP2022063872A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR102623475B1 (ko) | 2024-01-09 |
| CN107249616A (zh) | 2017-10-13 |
| IL284236B2 (en) | 2023-04-01 |
| ES2950901T3 (es) | 2023-10-16 |
| JP2018500385A (ja) | 2018-01-11 |
| JP6798998B2 (ja) | 2020-12-09 |
| IL252152B (en) | 2021-07-29 |
| TWI777260B (zh) | 2022-09-11 |
| JP2020090550A (ja) | 2020-06-11 |
| WO2016073949A1 (en) | 2016-05-12 |
| IL284236B (en) | 2022-12-01 |
| AU2015342767A1 (en) | 2017-06-15 |
| EP3215172A1 (en) | 2017-09-13 |
| US11618772B2 (en) | 2023-04-04 |
| US20180362599A1 (en) | 2018-12-20 |
| US11014970B2 (en) | 2021-05-25 |
| TW201629085A (zh) | 2016-08-16 |
| IL252152A0 (en) | 2017-07-31 |
| EP3215172A4 (en) | 2018-07-25 |
| EP3215172B1 (en) | 2023-04-26 |
| IL284236A (en) | 2021-08-31 |
| TWI708790B (zh) | 2020-11-01 |
| CA2966865A1 (en) | 2016-05-12 |
| KR20170083574A (ko) | 2017-07-18 |
| AU2021212006B2 (en) | 2023-08-31 |
| US20210122792A1 (en) | 2021-04-29 |
| JP2022063872A (ja) | 2022-04-22 |
| CA2966865C (en) | 2023-03-21 |
| AU2021212006A1 (en) | 2021-08-26 |
| TW202120525A (zh) | 2021-06-01 |
| AU2015342767B2 (en) | 2021-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1244201A1 (zh) | 芋螺毒素(conotoxin)肽的修饰和用途 | |
| ZA202004557B (en) | Modulatory polynucleotides | |
| MX2023010042A (es) | Polinucleotidos moduladores. | |
| WO2016149613A3 (en) | Selective mcl-1 binding peptides | |
| WO2016011306A3 (en) | Terminal modifications of polynucleotides | |
| SG10202001830PA (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| WO2016170348A3 (en) | Sarna compositions and methods of use | |
| MX2017009595A (es) | Compuestos antisenescentes y usos de los mismos. | |
| PH12018501114A1 (en) | Polypeptides inhibiting cd40l | |
| PL3515420T3 (pl) | Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek | |
| ZA201806844B (en) | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers | |
| WO2017075349A3 (en) | Selective mcl-1 binding peptides | |
| HK1221425A1 (zh) | 芋螺毒素(conotoxin)肽，其医药组合物和用途 | |
| HK1251481A1 (zh) | 使用白介素-17(il-17)拮抗剂治疗放射学阴性中轴型脊柱关节炎的方法 | |
| WO2014151369A3 (en) | Stabilized ezh2 peptides | |
| WO2015187521A3 (en) | Anti-blys antibodies | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| HK1256033A1 (zh) | 用於刺激免疫系统的肽 | |
| MX2017010883A (es) | Composicion para el tratamiento de la infertilidad. | |
| MX2017003216A (es) | Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica. | |
| PH12017500853A1 (en) | Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases | |
| HK1254231A1 (zh) | 米托-和厚朴酚化合物及其合成方法和用途 | |
| GB2546439B (en) | Ezrin-derived peptides and pharmaceutical compositions thereof | |
| MX2017006513A (es) | Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor. | |
| GB201518456D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHRG | Changes in the register |
Free format text: IADONATO, SHAWN, P Free format text: POSAKONY, JEFFREY JERARD |